PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2513232-3 1989 The augmented production of PAF by acetoacetate was also observed in the presence of autologous serum and was most prominent in the case of opsonized zymosan-stimulation rather than A23187-stimulation. Zymosan 150-157 PCNA clamp associated factor Homo sapiens 28-31 2513317-9 1989 The release of PAF in pertussis toxin-treated cells was also inhibited in cells stimulated with fMet-Leu-Phe or opsonized zymosan. Zymosan 122-129 PCNA clamp associated factor Homo sapiens 15-18 2847729-6 1988 PAF was however distinguished by its potent capacity to stimulate O2- and H2O2 production even at late stages of macrophage maturation (18 days), at which time both PMA and zymosan lacked significant effect. Zymosan 173-180 PCNA clamp associated factor Homo sapiens 0-3 2541198-6 1989 Calcium ionophore A23187, PMA, and opsonized zymosan also induced eosinophil degranulation but their peak effect after 10-min incubation with maximal release 14.7%, 12.9%, or 14.1%, respectively, was lower when compared with PAF. Zymosan 45-52 PCNA clamp associated factor Homo sapiens 225-228 2653576-7 1989 Our investigations have shown that eosinophils do possess the capacity to synthesize this mediator upon in-vitro challenge with the calcium ionophore A23187, zymosan particles coated with IgG and C3b (C3bi) or PAF at relatively high concentrations. Zymosan 158-165 PCNA clamp associated factor Homo sapiens 210-213 3126231-3 1988 PAF was produced after stimulation by calcium ionophore A23187 (IoA), opsonized zymosan (OpsZ), and PMA with a relative order of potency IoA much greater than OpsZ greater than PMA. Zymosan 80-87 PCNA clamp associated factor Homo sapiens 0-3 7532002-5 1995 Both VD and MC903 decreased PAF-increased expression of ICAM-1 on PMVECs, PMN chemotaxis to zymosan activated serum and histamine, and PMN aggregation induced by PAF significantly. Zymosan 92-99 PCNA clamp associated factor Homo sapiens 28-31 6430285-1 1984 Platelet activating factor (PAF) synthesized by human neutrophils challenged by opsonized zymosan or calcium ionophore was isolated from cells and buffer using Bligh and Dyer extraction following the addition of tracer amounts of tritiated-PAF. Zymosan 90-97 PCNA clamp associated factor Homo sapiens 0-26 6430285-1 1984 Platelet activating factor (PAF) synthesized by human neutrophils challenged by opsonized zymosan or calcium ionophore was isolated from cells and buffer using Bligh and Dyer extraction following the addition of tracer amounts of tritiated-PAF. Zymosan 90-97 PCNA clamp associated factor Homo sapiens 28-31 7164946-2 1982 Phagocytosis of zymosan, coated or not with complement, bacteria or immune complexes, stimulated the release of PAF-acether whereas that of latex particles was without effect. Zymosan 16-23 PCNA clamp associated factor Homo sapiens 112-115 6253571-3 1980 PAF release was dissociable from neutrophil degranulation by 1) the lack of correlation between PAF titers and extent of enzyme release for different stimuli, 2) the strict dependence of PAF release on the presence of extracellular Ca++, 3) the different kinetics for release of PAF and granule enzymes, and 4) the ability of neutrophils significantly depleted of azurophil and specific granule constituents to release normal levels of PAF when stimulated with opsonized zymosan. Zymosan 471-478 PCNA clamp associated factor Homo sapiens 0-3 6776037-5 1980 Phagocytic leucocytes (monocytes and PMNs) released PAF, physicochemically analogous to the PAF obtained by anaphylactic reactions in rabbits when challenged with zymosan, zymosan coated with complement, immune complexes, immunoglobulin aggregates or calcium ionophore A23187. Zymosan 163-170 PCNA clamp associated factor Homo sapiens 52-55 6776037-5 1980 Phagocytic leucocytes (monocytes and PMNs) released PAF, physicochemically analogous to the PAF obtained by anaphylactic reactions in rabbits when challenged with zymosan, zymosan coated with complement, immune complexes, immunoglobulin aggregates or calcium ionophore A23187. Zymosan 163-170 PCNA clamp associated factor Homo sapiens 92-95 8832056-15 1996 The incorporation of [3H]-acetate into [3H]-PAF induced by serum-treated zymosan in human PMNs was also inhibited concentration-dependently by cloricromene, with an IC50 of 105 microM. Zymosan 73-80 PCNA clamp associated factor Homo sapiens 44-47 8617285-6 1996 After phagocytic stimulation with serum-opsonized zymosan (OPZ), both macrophages and foam cells synthesized PAF transiently with maximal production (0.5-1.1 pmol PAF/microgram DNA, n = 5, corresponding to 4.0-8.8 pmol PAF/10(6) cells, as assessed by bioassay) occurring approximately 15 min after stimulation. Zymosan 50-57 PCNA clamp associated factor Homo sapiens 109-112 8617285-6 1996 After phagocytic stimulation with serum-opsonized zymosan (OPZ), both macrophages and foam cells synthesized PAF transiently with maximal production (0.5-1.1 pmol PAF/microgram DNA, n = 5, corresponding to 4.0-8.8 pmol PAF/10(6) cells, as assessed by bioassay) occurring approximately 15 min after stimulation. Zymosan 50-57 PCNA clamp associated factor Homo sapiens 163-166 8617285-6 1996 After phagocytic stimulation with serum-opsonized zymosan (OPZ), both macrophages and foam cells synthesized PAF transiently with maximal production (0.5-1.1 pmol PAF/microgram DNA, n = 5, corresponding to 4.0-8.8 pmol PAF/10(6) cells, as assessed by bioassay) occurring approximately 15 min after stimulation. Zymosan 50-57 PCNA clamp associated factor Homo sapiens 163-166 2828363-2 1988 The generation of platelet-activating factor (PAF) in response to complement-coated zymosan particles, ionophore A23187 and 12-O-tetradecanoylphorbol 13-acetate (TPA) was studied in human polymorphonuclear leukocytes (PMN). Zymosan 84-91 PCNA clamp associated factor Homo sapiens 18-44 2828363-2 1988 The generation of platelet-activating factor (PAF) in response to complement-coated zymosan particles, ionophore A23187 and 12-O-tetradecanoylphorbol 13-acetate (TPA) was studied in human polymorphonuclear leukocytes (PMN). Zymosan 84-91 PCNA clamp associated factor Homo sapiens 46-49 3035016-4 1987 PAF synthesis was induced by calcium ionophore A23187 (IoA), opsonized zymosan (OpsZ), and N-formyl-methionyl-leucyl-phenylalanine (FMLP) with the relative order of potency IoA much greater than OpsZ greater than FMLP. Zymosan 71-78 PCNA clamp associated factor Homo sapiens 0-3 3006836-8 1986 In contrast, PAF concentrations up to 10(-5) mol/L had only a minimal effect on the response to neutrophils to opsonized zymosan. Zymosan 121-128 PCNA clamp associated factor Homo sapiens 13-16 6724877-7 1984 Lower concentrations of Paf-acether (0.1 microM) were also able to increase oxygen radical production induced by low doses of zymosan and opsonized zymosan. Zymosan 126-133 PCNA clamp associated factor Homo sapiens 24-27 6724877-7 1984 Lower concentrations of Paf-acether (0.1 microM) were also able to increase oxygen radical production induced by low doses of zymosan and opsonized zymosan. Zymosan 148-155 PCNA clamp associated factor Homo sapiens 24-27 6885111-2 1983 This substance was identified as platelet-activating factor (PAF) on the basis of its sensitivity to phospholipase A2 and of its purification by thin-layer chromatography in identical conditions to those used to purify zymosan-induced PAF. Zymosan 219-226 PCNA clamp associated factor Homo sapiens 33-59 6885111-2 1983 This substance was identified as platelet-activating factor (PAF) on the basis of its sensitivity to phospholipase A2 and of its purification by thin-layer chromatography in identical conditions to those used to purify zymosan-induced PAF. Zymosan 219-226 PCNA clamp associated factor Homo sapiens 61-64 6885111-2 1983 This substance was identified as platelet-activating factor (PAF) on the basis of its sensitivity to phospholipase A2 and of its purification by thin-layer chromatography in identical conditions to those used to purify zymosan-induced PAF. Zymosan 219-226 PCNA clamp associated factor Homo sapiens 235-238 9841834-2 1999 Circulating and platelet-activating factor (PAF)-primed phagocyte luminol luminescence responses to complement-opsonized zymosan were increased in both groups of infected CF and non-CF children relative to uninfected CF children and healthy control children and adults. Zymosan 121-128 PCNA clamp associated factor Homo sapiens 16-42 9841834-2 1999 Circulating and platelet-activating factor (PAF)-primed phagocyte luminol luminescence responses to complement-opsonized zymosan were increased in both groups of infected CF and non-CF children relative to uninfected CF children and healthy control children and adults. Zymosan 121-128 PCNA clamp associated factor Homo sapiens 44-47 7514637-0 1994 Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. Zymosan 0-7 PCNA clamp associated factor Homo sapiens 115-141 1511005-1 1992 Production of platelet-activating factor (PAF) during opsonized zymosan stimulation of human polymorphonuclear leukocytes is dependent on the concentration of extracellular albumin and on the presence of exogenous fatty acids. Zymosan 64-71 PCNA clamp associated factor Homo sapiens 14-40 8227267-6 1993 Finally, PAF was comparatively determined by bioassay and HPLC-MS after extraction from the cell pellets and the supernatants of human polymorphonuclear neutrophils unstimulated or stimulated with opsonized zymosan. Zymosan 207-214 PCNA clamp associated factor Homo sapiens 9-12 1431137-2 1992 Earlier work from our laboratory has shown that the respiratory burst and homotypic aggregation response in these cells induced by opsonized particles (serum-treated zymosan, STZ), is strongly enhanced after pretreatment (priming) with PAF. Zymosan 166-173 PCNA clamp associated factor Homo sapiens 236-239 1511005-1 1992 Production of platelet-activating factor (PAF) during opsonized zymosan stimulation of human polymorphonuclear leukocytes is dependent on the concentration of extracellular albumin and on the presence of exogenous fatty acids. Zymosan 64-71 PCNA clamp associated factor Homo sapiens 42-45 1321621-3 1992 The effect of PAF was prominent in opsonized zymosan-stimulated eosinophils and in FMLP-stimulated neutrophils. Zymosan 45-52 PCNA clamp associated factor Homo sapiens 14-17 1586719-1 1992 The respiratory burst induced in human eosinophils by serum-treated zymosan (STZ) was found to be almost completely prevented by preincubation of the cells with WEB 2086, an antagonist of platelet-activating factor (PAF). Zymosan 68-75 PCNA clamp associated factor Homo sapiens 216-219 1321621-5 1992 The high responsiveness of unstimulated or opsonized zymosan-stimulated eosinophils to PAF to generate O2- may be relevant to the pathological changes at the loci of allergic reactions where eosinophils and PAF are crucially involved. Zymosan 53-60 PCNA clamp associated factor Homo sapiens 87-90 1321621-5 1992 The high responsiveness of unstimulated or opsonized zymosan-stimulated eosinophils to PAF to generate O2- may be relevant to the pathological changes at the loci of allergic reactions where eosinophils and PAF are crucially involved. Zymosan 53-60 PCNA clamp associated factor Homo sapiens 207-210 1655656-6 1991 Thus, differences in the effects of PAF receptor antagonists and dexamethasone compared with macrophage activation on zymosan-induced prostacyclin synthesis indicate that factors other than PAF or glucocorticoid-sensitive mechanisms contribute to this phenomenon. Zymosan 118-125 PCNA clamp associated factor Homo sapiens 190-193 2123719-2 1990 The amount of produced PAF in the presence of 5 microM lyso-PAF (without albumin) was 1.1 pmol/10 min per 2.5 X 10(6) cells, which was close to the level in the case of opsonized zymosan stimulation. Zymosan 179-186 PCNA clamp associated factor Homo sapiens 23-26 2123719-2 1990 The amount of produced PAF in the presence of 5 microM lyso-PAF (without albumin) was 1.1 pmol/10 min per 2.5 X 10(6) cells, which was close to the level in the case of opsonized zymosan stimulation. Zymosan 179-186 PCNA clamp associated factor Homo sapiens 60-63 1668119-4 1991 Preincubation with a small amount of PAF (5 x 10(-9) M) enhanced PMN superoxide release induced by various stimuli, such as phorbol myristate acetate (PMA), opsonized zymosan (OZ), calcium ionophore (A23187) and N-formyl-methionyl-leucyl-phenylalanine (FMLP). Zymosan 167-174 PCNA clamp associated factor Homo sapiens 37-40 1667989-6 1991 Both PMA and zymosan also significantly enhanced PMN CL in both RA (41.51 +/- 17.42, 40.0 +/- 26.51) and HS (43.42 +/- 17.28, 39.91 +/- 27.24), and those values were much higher than those of controls or via PAF stimulation, but, again, there was no difference between RA and HS groups. Zymosan 13-20 PCNA clamp associated factor Homo sapiens 208-211 1846746-7 1991 Two other PKC inhibitors, stearylamine and staurosporine, also blocked PAF synthesis following A23187 or opsonized zymosan stimulation. Zymosan 115-122 PCNA clamp associated factor Homo sapiens 71-74 1846746-8 1991 These experiments demonstrated that PKC activation was required for PAF synthesis in response to the calcium signal generated by A23187 or a receptor-mediated agonist, opsonized zymosan. Zymosan 178-185 PCNA clamp associated factor Homo sapiens 68-71 2246518-6 1990 Our results indicate that in eosinophils the phospholipase(s) responsible for the accumulation of the diglycerides and changes in [Ca2+]i during the initiation phase of the serum-treated zymosan response seem(s) to become associated with the signal transduction route only after priming with PAF. Zymosan 187-194 PCNA clamp associated factor Homo sapiens 292-295 2212673-7 1990 In cells that had been exposed to opsonized zymosan particles, the majority of the PAF was localized to the phagolysosomal fraction, with lesser amounts being detected in the membranous and granular fractions of the cells. Zymosan 44-51 PCNA clamp associated factor Homo sapiens 83-86